Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 12/20 | 0.64 |
| ▸ | KDM5C | P41229 | 5/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.61 |
| ▸ | KDM4A | O75164 | 4/20 | 0.61 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.61 |
| ▸ | KDM3A | Q9Y4C1 | 3/20 | 0.61 |
| ▸ | KDM6B | O15054 | 2/20 | 0.61 |
| ▸ | KDM5B | Q9UGL1 | 6/20 | 0.55 |
| ▸ | KDM5A | P29375 | 5/20 | 0.55 |
| ▸ | CTSA | P10619 | 1/20 | 0.53 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | BLVRB | P30043 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | KDM4B | O94953 | 1/20 | 0.49 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6225844 | 0.86 | KDM4C (0.58) | KDM4CKDM5CKDM4EKDM4AKDM2A | |
| SCHEMBL3721276 | 0.84 | KDM4C (0.54) | KDM4CKDM5CKDM4EKDM4AKDM2A | |
| SCHEMBL21311015 | 0.83 | KDM4C (0.59) | KDM4CKDM5CKDM4EKDM4AKDM2A | |
| SCHEMBL28883634 | 0.82 | KDM4C (0.66) | KDM4CKDM5CKDM4EKDM4AKDM2A | |
| SCHEMBL14226704 | 0.82 | CTSA (0.49) | KDM4CKDM5CKDM4EKDM4AKDM2A | |
| SCHEMBL14241075 | 0.82 | ADORA2A (0.52) | KDM4CKDM5CKDM4EKDM4AKDM2A | |
| SCHEMBL4901822 | 0.82 | MAOA (0.62) | KDM4CKDM5CKDM4EKDM4AKDM2A | |
| Bromide SCHEMBL6222773 | 0.81 | CTSA (0.48) | KDM4CKDM5CKDM4EKDM4AKDM2A | |
| SCHEMBL21310984 | 0.81 | KDM4C (0.68) | KDM4CKDM5CKDM4EKDM4AKDM2A | |
| SCHEMBL30775344 | 0.81 | KDM4C (0.68) | KDM4CKDM5CKDM4EKDM4AKDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102659774-A | Piperidine and piperazine derivatives as P2X3 antagonists | HOFFMANN LA ROCHE | 2012-09-12 | — | — | CN | disclosed |
| EP-1917262-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-12-14 | — | — | EP | disclosed |
| US-7491821-B2 | 2-(4-fluorophenyl)-4-propyl-oxazole-5-carboxylic acid {2-[4-(6-aminopyridin-2-yl)-piperazin-1-yl]-1-methyl-ethyl}amide; purinergic receptor antagonists, analgesics; urogenital, gastointestinal and respiratory system disorders | ROCHE PALO ALTO LLC (US) | 2009-02-17 | — | — | US | disclosed |
| CN-101282972-A | Piperidine and piperazine derivatives as P2X3 antagonists | HOFFMANN LA ROCHE (CH) | 2008-10-08 | — | — | CN | disclosed |
| EP-1917262-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007020194-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037974-A1 | Inhibitors of P2X3 | ROCHE PALO ALTO LLC | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037974-A1 | Inhibitors of P2X3 | P2RX3, P2RX4, P2RX5 | KDM4C 1206/4885KDM5C 1591/4885KDM4E 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.